Greenlight Re Announces First Quarter 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Greenlight Re Announces First Quarter 2014 Financial Results

GRAND CAYMAN, Cayman Islands, May 5, 2014 (GLOBE NEWSWIRE) -- Greenlight Capital Re, Ltd. (Nasdaq: GLRE ) today announced financial results for the first quarter ended March 31, 2014. Greenlight Re reported net loss of $8.9 million for the first quarter of 2014 compared to net income of $56.7 million for the same period in 2013. The net loss per share was $0.24 compared to fully diluted net income per share of $1.52 for the same period in 2013.

Fully diluted adjusted book value per share was $27.61 as of March 31, 2014, a 17.7% increase from $23.45 per share as of March 31, 2013. 

Financial and operating highlights for Greenlight Re for the first quarter ended March 31, 2014 include:

  • Gross written premiums of $118.9 million, compared to $127.0 million in the first quarter of 2013; net earned premiums were $111.7 million, an increase from $109.5 million reported in the prior-year period. 
     
  • Underwriting income of $6.5 million, compared to underwriting income of $1.9 million in the first quarter of 2013. 
     
  • A net investment loss of 0.7% on Greenlight Re's investment portfolio managed by DME Advisors, LP compared to a net investment gain of 5.8% in the first quarter of 2013.

"Our underwriting portfolio performed adequately during the first quarter of 2014," said Bart Hedges, Chief Executive Officer of Greenlight Re. "We continue to focus our underwriting efforts on creating long term relationships in areas of the market that we feel provide attractive returns to our shareholders."

"Our investment portfolio had a small loss as we continue to be defensively positioned in an uncertain investment environment," stated David Einhorn, Chairman of the Board of Directors. "Our underwriting team continues to proceed carefully under challenging reinsurance market conditions."

Conference Call Details

Greenlight Re will hold a live conference call to discuss its financial results for the first quarter March 31, 2014 on Tuesday, May 6, 2014 at 9:00 a.m. Eastern time.  The conference call title is Greenlight Capital Re, Ltd. First Quarter 2014 Earnings Call.

To participate in the Greenlight Capital Re, Ltd. First Quarter 2014 Earnings Call, please dial in to the conference call at:

U.S. toll free    1-888-317-6016   
International     1-412-317-6016

The conference call can also be accessed via webcast at:

http://services.choruscall.com/links/glre140506.html

A telephone replay of the call will be available from 11:00 a.m. Eastern time on May 6, 2014 until 9:00 a.m. Eastern time on May 14, 2014.  The replay of the call may be accessed by dialing 1-877-344-7529 (U.S. toll free) or 1-412-317-0088 (international), access code 10043451. An audio file of the call will also be available on the Company's website, www.greenlightre.ky .

Regulation G

Fully diluted adjusted book value per share is a non-GAAP measure and represents basic adjusted book value per share combined with the impact from dilution of share based compensation including in-the-money stock options and RSUs as of any period end. Book value is adjusted by subtracting the amount of the non-controlling interest in joint venture from total shareholders' equity to calculate adjusted book value. We believe that long term growth in fully diluted adjusted book value per share is the most relevant measure of our financial performance. In addition, fully diluted adjusted book value per share may be of benefit to our investors, shareholders and other interested parties to form a basis of comparison with other companies within the reinsurance industry.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the U.S. federal securities laws. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the U.S. Federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements made on behalf of the Company. These risks and uncertainties include the impact of general economic conditions and conditions affecting the insurance and reinsurance industry, the adequacy of our reserves, our ability to assess underwriting risk, trends in rates for property and casualty insurance and reinsurance, competition, investment market fluctuations, trends in insured and paid losses, catastrophes, regulatory and legal uncertainties and other factors described in our annual report on Form 10-K filed with the Securities Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Greenlight Capital Re, Ltd.

Greenlight Re ( www.greenlightre.ky ) is a NASDAQ listed company with specialist property and casualty reinsurance companies based in the Cayman Islands and Ireland.  Greenlight Re provides a variety of custom-tailored reinsurance solutions to the insurance, risk retention group, captive and financial marketplaces.  Established in 2004, Greenlight Re selectively offers customized reinsurance solutions in markets where capacity and alternatives are limited.  With a focus on deriving superior returns from both sides of the balance sheet, Greenlight Re's assets are managed according to a value-oriented equity-focused strategy that complements the Company's business goal of long-term growth in book value per share.

GREENLIGHT CAPITAL RE, LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS
     
March 31, 2014 and December 31, 2013  
(expressed in thousands of U.S. dollars, except per share and share amounts)
     
  March 31, 2014 December 31, 2013
  (unaudited) (audited)
Assets    
Investments    
Debt instruments, trading, at fair value  $ 4,330  $ 4,312
Equity securities, trading, at fair value 1,227,911 1,282,156
Other investments, at fair value 110,709 107,211
Total investments 1,342,950 1,393,679
Cash and cash equivalents 4,283 3,722
Restricted cash and cash equivalents 1,228,916 1,334,074
Financial contracts receivable, at fair value 82,623 104,048
Reinsurance balances receivable 185,833 167,340
Loss and loss adjustment expenses recoverable 16,192 16,829
Deferred acquisition costs, net 53,046 51,797
Unearned premiums ceded 6,050 3,173
Notes receivable 15,917 16,049
Other assets 5,475 4,565
Total assets  $ 2,941,285  $ 3,095,276
Liabilities and equity    
Liabilities    
Securities sold, not yet purchased, at fair value  $ 986,408  $ 1,111,690
Financial contracts payable, at fair value 23,659 18,857
Due to prime brokers 285,896 314,702
Loss and loss adjustment expense reserves 329,012 329,894
Unearned premium reserves 177,332 173,057
Reinsurance balances payable 43,382 38,789
Funds withheld 9,804 10,126
Other liabilities 12,598 11,857
Total liabilities 1,868,091 2,008,972
Equity    
Preferred share capital (par value $0.10; authorized, 50,000,000; none issued) — —
Ordinary share capital (Class A: par value $0.10; authorized, 100,000,000; issued and outstanding, 30,958,744 (2013: 30,791,865): Class B: par value $0.10; authorized, 25,000,000; issued and outstanding, 6,254,949 (2013: 6,254,949)) 3,721 3,705
Additional paid-in capital 497,574 496,622
Retained earnings 542,387 551,268
Shareholders' equity attributable to shareholders 1,043,682 1,051,595
Non-controlling interest in joint venture 29,512 34,709
Total equity 1,073,194 1,086,304
Total liabilities and equity  $ 2,941,285  $ 3,095,276
 
 
GREENLIGHT CAPITAL RE, LTD.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
     
For the three months ended March 31, 2014 and 2013 
(expressed in thousands of U.S. dollars, except per share and share amounts)
     
     
  Three months ended March 31,
  2014 2013
Revenues    
Gross premiums written  $ 118,901  $ 126,964
Gross premiums ceded (5,940) 3,978
Net premiums written 112,961 130,942
Change in net unearned premium reserves (1,272) (21,471)
Net premiums earned 111,689 109,471
Net investment income (loss) (10,150) 61,139
Other income, net 441 389
Total revenues 101,980 170,999
Expenses    
Loss and loss adjustment expenses incurred, net 67,363 66,278
Acquisition costs, net 37,796 41,296
General and administrative expenses 6,459 3,760
Total expenses 111,618 111,334
Income (loss) before income tax expense (9,638) 59,665
Income tax (expense) benefit 560 (308)
Net income (loss) including non-controlling interest (9,078) 59,357
(Income) loss attributable to non-controlling interest in joint venture 197 (2,624)
Net income (loss) $ (8,881)  $ 56,733
     
Earnings (loss) per share    
Basic $ (0.24)  $ 1.54
Diluted $ (0.24)  $ 1.52
     
Weighted average number of ordinary shares used in the determination of earnings (loss) per share    
Basic 36,808,386 36,730,315
Diluted 36,808,386 37,424,894
 
The following table provides the ratios for the three months ended March 31, 2014 and 2013: 
     
  Three months ended March 31, Three months ended March 31,
  2014 2013
  Frequency Severity Total Frequency Severity Total
             
Loss ratio 62.8% 18.8% 60.3% 71.2% (676.4)% 60.5%
Acquisition cost ratio 34.9% 16.1% 33.8% 37.6% 46.2% 37.7%
Composite ratio 97.7% 34.9% 94.1% 108.8% (630.2)% 98.2%
Internal expense ratio     4.8%     4.5%
Corporate expense ratio     1.0%     (1.0)%
Combined ratio     99.9%     101.7%

Garrett Edson ICR (203) 682-8331 Media: Brian Ruby ICR (203) 682-8268

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CatsOnly: Building Community with Feline-Centric Care

Updated Category News Views 36

Cats Only: Not Just Another Vet Office Sometimes, a new kind of passion-driven initiative gets your attention. That's where CatsOnly™ steps in—a feline-exclusive clinic that’s not about the bottom line but about building connections and elevating that ultimate feline care game. Their latest gig, dubbed Ginger’s Giving Season, is all about bridging the gap between...

Continue Reading
Paulex Bio's Grant Fuels Bold Diabetes Research Push

Updated Category News Views 94

Cracking the Diabetes Code: A New Hope Emerging It ain't every day you hear about a biotech outfit snagging an NIH Fast-Track grant with the potential to upend diabetes treatment, but Paulex Bio's recent score turns heads. Their brainchild, PAL-119, promises to tackle diabetes not by slapping a band-aid on symptoms, but by getting to the rotten core of the disease: the...

Continue Reading
Kia's Landmark Triple Win at 2026 Car Awards

Updated Category News Views 85

Kia Makes History Well, folks, Kia has pulled off what many might have thought impossible. They snagged not one, not two, but three of Germany's Golden Steering Wheel awards. That's a real hat trick and a first for any non-European auto brand. With competition hotter than a stolen Tesla, Kia's not just keeping pace but setting it. The Golden Steering Wheel is one of those...

Continue Reading
Resideo's AI-Powered Pro-IQ™ Predict: HVAC Revolution

Updated Category News Views 314

Is AI the Savior for HVAC Breakdowns? You ever been stuck on a freezing night with a busted heater? It's a classic tale: equipment goes south just when you need it most. But what if someone told you AI could catch HVAC issues before they send you running for the wool socks? Enter Resideo Technologies' latest brainchild, Pro-IQ™ Predict. This isn't some run-of-the-mill...

Continue Reading
Florida's Insurance Premiums: Why They Keep Skyrocketing

Updated Category News Views 61

What’s Driving Up These Premiums? If you’ve ever felt like your wallet gets lighter every time you pay your insurance premium, welcome to the club. It seems like the cost of insurance in Florida is like a runaway train. But don't just blame the hurricanes. Yeah, they definitely play their part, but there’s a bigger picture lurking behind those price tags. Weather...

Continue Reading
Dixie Group Gears Up for Q3 Earnings Call Reveal

Updated Category News Views 165

Anticipation Builds for The Dixie Group's Q3 Results Ah, the smell of anticipation in the air—it's earnings season again, folks! For those keeping a keen eye, The Dixie Group, Inc. (OTCQB: DXYN) sets the stage for the big unveil of its 2026 third-quarter results. They're rolling out the red carpet for investors on Thursday, November 12, 2026, at 11:30 a.m. Eastern Time,...

Continue Reading
Ceipal Ora: AI Revolution for Staffing Firms Begins

Updated Category News Views 65

Staffing Game Changer: Enter Ceipal Ora Folks in the staffing arena, hold onto your hats—Ceipal's rolling out something that could turn the tables. This new AI hotshot, Ceipal Ora, claims to be not just another AI patch on an old coat but the whole new garment itself. It's not just some afterthought glued to a platform; it's the glue holding the operations together,...

Continue Reading
CeQur Revolutionizes Insulin Delivery with Wearable Patch

Updated Category News Views 67

A Patch to Simplify Mealtime Insulin So, it turns out CeQur is stepping up to the plate with their new wearable insulin patch called CeQur Simplicity. They just rolled it out nationally, and it's not your grandmother's insulin delivery method—this one sticks around for a whole week with some nifty up-to-1-unit dosing. If you're shoving insulin needles or pens into your...

Continue Reading
Yeastar 2026 Summit: AI, Growth, and Global Vision

Updated Category News Views 32

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Continue Reading
Otus Earns Top Spot in Education AI at Innovation Awards

Updated Category News Views 85

Acknowledging AI's Growing Role in Education Times are changing, and the classroom ain't what it used to be. Enter Otus, a platform that's breaking the mold by bringing artificial intelligence smack dab into K-12 education. They've bagged the 2026 SmartBrief Innovation Award in AI within the Education category. Clocking in at serving nearly 100 school districts, it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Canine Cancer Treatment Through Innovation

Updated Category News Views 167

Revolutionizing Canine Cancer Care Through Innovation The world of veterinary medicine has seen incredible progress in caring for dogs with cancer. Thrive Pet Healthcare is making significant efforts to improve the quality of care for these pets. Their partnership with FidoCure, a leader in canine oncology, highlights their dedication to helping pet owners access...

Continue Reading
BioAtla to Showcase Innovative Cancer Therapies at Major Events

Updated Category News Views 189

BioAtla to Showcase Innovative Cancer Therapies at Major Events BioAtla, Inc. (Nasdaq: BCAB), a prominent player in the biotechnology sector, focuses on advancing Conditionally Active Biologic (CAB) antibody therapeutics aimed at treating solid tumors. With a commitment to innovation and patient care, the company announced that two of its research abstracts have been...

Continue Reading
Liberty Star Minerals' Geophysical Breakthrough in Gold Discovery

Updated Category News Views 158

Revelation in Gold Exploration Liberty Star Minerals, an innovative exploration company, has recently made headlines with the successful induced polarization (IP) and resistivity testing at the Red Rock Canyon Gold Project. This project is a part of their extensive Hay Mountain Project in southeastern Arizona. These tests are pivotal in the ongoing search for strategic...

Continue Reading
Malibu Boats Celebrates Another Award for the Wakesetter 23 LSV

Updated Category News Views 135

Malibu Boats Wakesetter 23 LSV Triumphs Again Malibu Boats, Inc. (NASDAQ: MBUU) continues to solidify its position as the leader in the watersports boating industry. The iconic Malibu Wakesetter 23 LSV has been awarded the prestigious title of Wakesurf and Wakeboard Boat of the Year for the sixth consecutive year by the WakeWorld Riders Choice Awards. This remarkable...

Continue Reading
Alto Neuroscience Faces Deadline for Securities Fraud Lawsuit

Updated Category News Views 100

Understanding Alto Neuroscience's Legal Challenges Alto Neuroscience, Inc. (NYSE: ANRO) is currently in the spotlight due to a securities fraud class action lawsuit filed on behalf of its investors. The company has faced scrutiny regarding its initial public offering (IPO) and claims that misrepresentations were made about its flagship product, ALTO-100, a treatment...

Continue Reading